# Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

> **NCT05532059** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Cholangiocarcinoma

## Interventions

- **DRUG:** Lenvatinib, tislelizumab, gemcitabine and cisplatin
- **DRUG:** gemcitabine and cisplatin

## Key facts

- **NCT ID:** NCT05532059
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-31
- **Primary completion:** 2025-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532059, "Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05532059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*